Skip to main content

Table 2 Per protocol analysis showing mean ± SD per patient costs and mean (95% CI) cost differences in 2012 US$ for AL vs. AN given for falciparum (upper panel) or vivax (lower panel) malaria in usual care and trial settings

From: Cost-effectiveness of artemisinin–naphthoquine versus artemether–lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children

 

AL

AN

AN vs. AL

Falciparum malaria

 Number

92

94

 

 Anti-malarial treatment

1.58 ± 0.56

12.04 ± 3.35

10.46 (9.77 to 11.16)*

 Paracetamol

0.003 ± 0.002

0.003 ± 0.003

0.000 (− 0.001 to 0.001)

 Clinic visits

5.53 ± 1.63

5.23 ± 0.77

− 0.29 (− 0.66 to 0.08)

 Total (usual care)

7.66 ± 2.29

17.28 ± 3.40

9.61 (8.78 to 10.45)*

 Excess costs for trial

54.71 ± 1.31

49.56 ± 1.54

− 5.15 (− 5.56 to − 4.74)*

 Total (trial)

62.37 ± 3.21

66.84 ± 3.83

4.46 (3.44 to 5.49)*

Vivax malaria

 Number

20

26

 

 Anti-malarial treatment

1.41 ± 0.48

12.46 ± 2.72

11.05 (9.93 to 12.16)*

 Paracetamol

0.003 ± 0.003

0.002 ± 0.002

− 0.000 (− 0.002 to 0.001)

 Clinic visits

5.12 ± 0.00

5.32 ± 1.04

0.20 (− 0.27 to 0.67)

 Total (usual care)

7.41 ± 1.16

17.78 ± 3.20

10.38 (9.00 to 11.76)*

 Excess costs for trial

54.72 ± 0.13

49.76 ± 0.43

− 4.96 (− 5.16 to − 4.76)*

 Total (trial)

62.12 ± 1.14

67.54 ± 3.45

5.42 (3.95 to 6.89)*

  1. P < 0.001 vs. AL; negative cost differences indicate cost-savings associated with AN